Adaptimmune Therapeutics (NASDAQ:ADAP) Adrian Rawcliffe talks to Proactive about the Oxford, UK-based biotechnology group's recent updates on its late-stage clinical pipeline assets to treat various cancers. Rawcliffe says among its many clinical milestones, it intends to file a BLA to the FDA in the fourth quarter of 2022 for the treatment of synovial sarcoma. Rawcliffe adds the company is well capitalized to deliver on these milestones.
Adaptimmune Therapeutics shares update on its late-stage clinical pipeline assets to treat cancer
